Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study

OBJECTIVE: To conduct a phase II trial of the combination of carboplatin, prednisone, and everolimus in metastatic castrate–resistant prostate cancer (mCRPC) as mTOR inhibition can overcome resistance to chemotherapy in prostate cancer. METHODS: Patients with progressive mCRPC pretreated with doceta...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Urology
Autors principals: Vaishampayan, Ulka, Shevrin, Daniel, Stein, Mark, Heilbrun, Lance, Land, Susan, Stark, Karri, Li, Jing, Dickow, Brenda, Heath, Elisabeth, Smith, Daryn, Fontana, Joseph
Format: Artigo
Idioma:Inglês
Publicat: 2015
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6902637/
https://ncbi.nlm.nih.gov/pubmed/26375845
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.urology.2015.08.008
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars